Effi cacy of the biological treatments based on ACR70 response in rheumatoid arthritis: Indirect comparison and meta-regression using Bayes-model;A rheumatoid arthritisben alkalmazott biológiai kezelések hatásossága az ACR70-végpont szerint: indirekt összehasonlítás és metaregresszió Bayes-modell alkalmazásával

Orvosi Hetilap

Volumn 152, Issue 23, 2011, Pages 919-928

  Brodszky, Valentin ^a  

^a Institute of Entrepreneurship and Innovation   (Hungary)

Author keywords

abatacept; adalimumab; biological treatment; certolizumab; etanercept; golimumab; infl iximab; metaanalysis; rheumatoid arthritis; rituximab; tocilizumab

Indexed keywords

ANTIRHEUMATIC AGENT; PLACEBO;

BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; DISEASE DURATION; DRUG EFFICACY; HUMAN; META ANALYSIS; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BAYES THEOREM; BIOLOGICAL MARKERS; BIOLOGICAL THERAPY; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MATHEMATICAL COMPUTING; METHOTREXATE; ODDS RATIO; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 79957625952     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2011.29138     Document Type: Review

References (43)

1. Czirják L., Gergely P., Rojkovich B.: A rheumatoid arthritis korai felismerésének jelentosége. Háziorvos Továbbképzo Szemle, 2002, 7, 497-500.
2. Kiss, C. G., Lovei, C., Süto, G. és mtsai: Prevalence of rheumatoid arthritis in the South-Transdanubian region of Hungary based on a representative survey of 10,000 inhabitants. J. Rheumatol., 2005, 32, 1688-1690. (Pubitemid 41324804)
3. Inotai, A., Hankó, B., Mészáros, A.: Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information. Pharmacoepidemiol. Drug Saf., 2010, 19, 183-190.
4. Szekanecz Z., Poór G.: A reumatoid arthritis kezelése a célértékek alapján. M. Reumatol., 2010, 51, 68-71.
5. Géher P.: A rheumatoid arthritis gyógyszeres kezelése. Medicus Universalis, 2000, 33, 245-250.
6. Péntek M., Poór G., Czirják L.: Magyarországi reumatoid arthritises betegek egészségi állapota, egészségügyi szolgáltatások igénybevétele, gondozása és munkaké pessége keresztmetszeti kérdoíves vizsgálat alapján. M. Reumatol., 2007, 48, 42-57.
7. Szekanecz Z.: Bázisterápiás szerek összehasonlítása rheumatoid arthritisben. Magyar Immunológia, 2008, 7, 50-51.
8. Szucs G.: TNF-alfa-gátló kezelés methotrexat vagy leflunomid kombinációban rheumatoid arthritisben-.,real-life" tapasztala-tok. M. Reumatol., 2009, 50, 203-206.
9. Higgins, J. P. T., Green, S.: Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, Ltd., Chichester, UK, 2005.
10. Ades, A. E., Sculpher, M., Sutton, A. és mtsai: Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmac-oeconomics, 2006, 24, 1-19. (Pubitemid 43197227)
11. Nixon, R. M., Bansback, N., Brennan, A.: Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Statistics in Medicine, 2007, 26, 1237-1254. (Pubitemid 46380839)
12. Bathon, J. M., Martin, R. W., Fleischmann, R. M. és mtsai: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med., 2000, 343, 1586-1593. (Pubitemid 32162981)
13. Breedveld, F. C., Weisman, M. H., Kavanaugh, A. F. és mtsai: The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum., 2006, 54, 26-37. (Pubitemid 43122183)
14. Cohen, S. B., Emery, P., Greenwald, M. W. és mtsai: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum., 2006, 54, 2793-2806. (Pubitemid 44497758)
15. Edwards, J. C., Szczepanski, L., Szechinski, J. és mtsai: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med., 2004, 350, 2572-2581. (Pubitemid 38758544)
16. Emery, P., Breedveld, F. C., Hall, S. és mtsai: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet, 2008, 372, 375-382.
17. Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A. és mtsai: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum., 2006, 54, 1390-1400.
18. Emery, P., Fleischmann, R. M., Moreland, L. W. és mtsai: Goli-mumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum., 2009, 60, 2272-2283.
19. Emery, P., Keystone, E., Tony, H. P. és mtsai: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis., 2008, 67, 1516-1523.
20. Fleischmann, R., Vencovsky, J., van Vollenhoven, R. F. és mtsai: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis., 2009, 68, 805-811.
21. Furst, D. E., Schiff, M. H., Fleischmann, R. M. és mtsai: Adali-mumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheu-matol., 2003, 30, 2563-2571. (Pubitemid 37549331)
22. Genovese, M. C., Becker, J. C., Schiff, M. és mtsai: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med., 2005, 353, 1114-1123. (Pubitemid 41317434)
23. Genovese, M. C., McKay, J. D., Nasonov, E. L. és mtsai: Inter-leukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum., 2008, 58, 2968-2980.
24. Jones, G., Sebba, A., Gu, J. és mtsai: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis., 2010, 69, 88-96.
25. Keystone, E., Heijde, D., Mason, D. Jr. és mtsai: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum., 2008, 58, 3319-3329.
26. Keystone, E. C., Genovese, M. C., Klareskog, L. és mtsai: Golimu-mab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann. Rheum. Dis., 2009, 68, 789-796.
27. Keystone, E. C., Kavanaugh, A. F., Sharp, J. T. és mtsai: Radio-graphic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum., 2004, 50, 1400-1411. (Pubitemid 38608061)
28. Klareskog, L., van der Heijde, J., de Jager, J. P. és mtsai: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet, 2004, 363, 675-681. (Pubitemid 38296553)
29. Kremer, J. M., Genant, H. K., Moreland, L. W. és mtsai: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med., 2006, 144, 865-876. (Pubitemid 46768126)
30. Kremer, J. M., Westhovens, R., Leon, M. és mtsai: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med., 2003, 349, 1907-1915. (Pubitemid 37409707)
31. Maini, R., St. Clair, E. W., Breedveld, F. és mtsai: Infliximab (chi-meric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet, 1999, 354, 1932-1939.
32. Miyasaka, N.: Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod. Rheumatol., 2008, 18, 252-262.
33. Moreland, L. W., Schiff, M. H., Baumgartner, S. W. és mtsai: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med., 1999, 130, 478-486. (Pubitemid 29135800)
34. Nishimoto, N., Hashimoto, J., Miyasaka, N. és mtsai: Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radio-graphic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis., 2007, 66, 1162-1167. (Pubitemid 47309731)
35. Smolen, J., Landewe, R. B., Mease, P. és mtsai: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis., 2009, 68, 797-804.
36. Smolen, J. S., Beaulieu, A., Rubbert-Roth, A. és mtsai: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet, 2008, 371, 987-997. (Pubitemid 351392039)
37. Smolen, J. S., Kay, J., Doyle, M. K. és mtsai: Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet, 2009, 374, 210-221.
38. St. Clair, E. W., van der Heijde, D. M., Smolen, J. S. és mtsai: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum., 2004, 50, 3432-3443. (Pubitemid 39488667)
39. Van de Putte, L. B., Atkins, C., Malaise, M. és mtsai: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheu-matic drug treatment has failed. Ann. Rheum. Dis., 2004, 63, 508-516. (Pubitemid 38530193)
40. Weinblatt, M., Combe, B., Covucci, A. és mtsai: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum., 2006, 54, 2807-2816. (Pubitemid 44497759)
41. Weinblatt, M. E., Keystone, E. C., Furst, D. E. és mtsai: Adalimu-mab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum., 2003, 48, 35-45. (Pubitemid 36091645)
42. Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D. és mtsai: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med., 1999, 340, 253-259. (Pubitemid 29063266)
43. Westhovens, R., Yocum, D., Han, J. és mtsai: The safety of inflixi-mab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum., 2006, 54, 1075-1086. (Pubitemid 43672920)